Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer

Cancer

Volumn 116, Issue 9, 2010, Pages 2081-2089

  Ejlertsen, Bent ^a,b   Mouridsen, Henning T ^a,b   Jensen, Maj Britt ^a   Andersen, Jørn ^c   Andersson, Michael ^b   Kamby, Claus ^d   Knoop, Ann S ^e  

^a Danish Breast Cancer Cooperative Group   (Denmark)

^b Building 4262 Rigshospitalet ^*  (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adjuvant chemotherapy; Antineoplastic agents; Breast neoplasms; Clinical trials; Humans

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; LEVAMISOLE; METHOTREXATE;

ACUTE LEUKEMIA; ADULT; AGRANULOCYTOSIS; ARTICLE; AXILLARY LYMPH NODE; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR VOLUME;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEVAMISOLE; METHOTREXATE; MIDDLE AGED; PREMENOPAUSE;

EID: 77951456852     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24969     Document Type: Article

References (27)

1. Nissen-Meyer R, Kjellgren K, Mansson B. Preliminary report from the Scandinavian adjuvant chemotherapy study group. Cancer Chemother Rep. 1971;55:561-566.
2. Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med. 1975;292:117-122.
3. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405-410.
4. [No authors listed] Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med. 1988;319:1681-1692.
5. [No authors listed] Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992;339:71-85.
6. [No authors listed] Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942.
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
8. Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children [serial online]. Cochrane Database Syst Rev. 2008;(1):CD002290.
9. Martin RJ, Robertson AP. Mode of action of levamisole and pyrantel, anthelmintic resistance, E153 and Q57. Parasitology. 2007;134:1093-1104.
10. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol. 1989;7:1447-1456.
11. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-326.
12. Friis T, Engel AM, Klein BM, Rygaard J, Houen G. Levamisole inhibits angiogenesis in vitro and tumor growth in vivo. Angiogenesis. 2005;8:25-34. (Pubitemid 41223836)
13. Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat. 1983;3:91-95. (Pubitemid 13102091)
14. Moller S, Jensen MB, Ejlertsen B, et al. The clinical data-base and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008;47:506-524. (Pubitemid 351878431)
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
16. World Health Organization. International Histological Classification of Tumours. 2nd ed. Geneva, Switzerland: World Health Organization; 1981.
17. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17:343-346. (Pubitemid 26342716)
18. Andersson M, Jensen MB, Engholm G, Storm HH. Risk of second primary cancer among patients with early operable breast cancer registered or randomised in Danish Breast Cancer Cooperative Group (DBCG) protocols of the 77, 82 and 89 programmes during 1977-2001. Acta Oncol. 2008;47:755-764.
19. [No authors listed] Increased breast-cancer recurrence rate after adjuvant therapy with levamisole. A preliminary report. Executive Committee of the Danish Breast Cancer Cooperative Group. Lancet. 1980;2:824-827.
20. Bedard PL, Krzyzanowska MK, Pintilie M, Tannock IF. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol. 2007;25:3482-3487. (Pubitemid 47310887)
21. O'Shaughnessy JA. Oral alkylating agents for breast cancer therapy. Drugs. 1999;58:1-9. (Pubitemid 30192608)
22. Bonadonna G, Moliterni A, Zambetti M, et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [serial online]. BMJ. 2005;330:217.
23. Ejlertsen B, Mouridsen HT, Jensen MB. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premenopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Acta Oncol. 2008;47:662-671. (Pubitemid 351878453)
24. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15:1858-1869.
25. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol. 1999;17:3374-3388.
26. Brincker H, Rose C, Rank F, et al. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol. 1987;5:1771-1778. (Pubitemid 18020842)
27. Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006;24:5769-5779. (Pubitemid 46646480)